Jing Hu

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff P. Sharman, Michael Hawkins, Kathryn S. Kolibaba et al. · Blood · 2015 · 184 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells

Hongyu Li, Jing Hu, Shuhong Wu et al. · Oncotarget · 2015 · 147 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Paul M. Barr, Gene Saylors, Stephen E. Spurgeon et al. · Blood · 2016 · 142 citations

Medicine, Pharmacology, Pharmacotherapy +7

Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/β-catenin signalling pathway

Dehai Che, Shuai Zhang, Zihan Jing et al. · Molecular Immunology · 2017 · 132 citations

Life Sciences, Cell Biology, Oncology +14

Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution

Hongyi Zhang, Xuexin Yu, Jianfeng Ye et al. · Cancer Cell · 2023 · 116 citations · Full text

Life Sciences, Cell Biology, Immunology +17